| scholarly article | Q13442814 |
| P2093 | author name string | Lin Yang | |
| Jing Wang | |||
| Jian Sun | |||
| Suna Zhou | |||
| Zhenyi Liu | |||
| Haibo Chen | |||
| Hanjie Yi | |||
| Qiuyun Luo | |||
| Xianglei Yan | |||
| Guangfeng Wang | |||
| Luping Yuan | |||
| DaJun Yang | |||
| MiaoZhen Qiu | |||
| Wentao Pan | |||
| P2860 | cites work | Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia | Q24313505 |
| Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma | Q24613755 | ||
| ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Q28266682 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane | Q29616354 | ||
| ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor | Q29616727 | ||
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors | Q33393931 | ||
| Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer | Q33400716 | ||
| Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma | Q33416332 | ||
| B-cell receptor signaling as a driver of lymphoma development and evolution | Q34398579 | ||
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
| Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 | ||
| Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns | Q36448578 | ||
| New therapeutic targets and drugs in non-Hodgkin's lymphoma | Q37886574 | ||
| Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases | Q37921609 | ||
| Management of diffuse large B-cell lymphoma (DLBCL). | Q38345599 | ||
| Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies | Q38351184 | ||
| Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas | Q38351380 | ||
| Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma | Q38413580 | ||
| p53 in survival, death and metabolic health: a lifeguard with a licence to kill | Q38540071 | ||
| B-cell receptor pathway modulators in NHL. | Q38659428 | ||
| ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia | Q38949201 | ||
| Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia | Q39006397 | ||
| BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma | Q40357519 | ||
| Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. | Q40716705 | ||
| Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 | ||
| Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Q46112292 | ||
| Cancer statistics, 2018. | Q47191906 | ||
| Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy | Q47302512 | ||
| A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. | Q52714998 | ||
| Targeting the B cell receptor pathway in non-Hodgkin lymphoma. | Q54977449 | ||
| Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine | Q57496075 | ||
| Diffuse large B-cell lymphoma | Q60019700 | ||
| Non-Hodgkin lymphoma | Q84629067 | ||
| Selective targeting of antiapoptotic BCL-2 proteins in cancer | Q88918023 | ||
| Venetoclax active and safe in non-Hodgkin lymphoma | Q89895543 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P921 | main subject | diffuse large B-cell lymphoma | Q2626074 |
| P577 | publication date | 2020-02-24 | |
| P1433 | published in | Oncology Research | Q15750114 |
| P1476 | title | A novel BCL-2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-P53 inhibitor in Diffuse Large B-Cell Lymphoma |
| Q97531386 | MDM2 inhibition: an important step forward in cancer therapy | cites work | P2860 |
Search more.